Consolidated PAT +27% YoY to ₹26.7 Cr as revenue jumps 43%, margins still below last year
PAT +26.56% YoY · revenue +43.11% · margins compressing
₹247.69 Cr
+43.11% YoY
₹26.75 Cr
+26.56% YoY
10.61%
-1.3pp YoY
₹1.32
Standard Engineering Technology (formerly Standard Glass Lining Technology) posted consolidated revenue of ₹247.69 Cr for Q1 FY27, up 43.1% YoY from ₹173.07 Cr and up 9.3% QoQ from ₹226.68 Cr. Consolidated PAT (before minority interest) came in at ₹26.75 Cr, up 26.6% YoY and 26.9% QoQ. No exceptional items or one-offs feature in either period, so these are clean reported-to-reported comparisons. The headline growth is real, but profit grew meaningfully slower than revenue on a YoY basis — the classic signature of margin compression rather than a one-off drag.
Q1 FY-2027 vs prior quarters
That shows up directly in the margins: net profit margin (PAT/total income) fell to 10.61% from 11.86% a year ago (-125 bps), and EBITDA-ex-other-income margin (OPM) fell to 16.00% from 17.08% (-108 bps). Both metrics did recover sequentially — NPM was 9.13% and OPM 13.91% in Q4 FY26 — so the commodity-cost and manpower-investment pressure management flagged last quarter is easing, but neither margin has yet clawed back to where it stood a year ago. On the standalone (parent-only) book the divergence from consolidated is sharper: standalone PAT rose just 10.7% YoY to ₹16.33 Cr even as standalone revenue grew 50.6%, because a large other-income/treasury contribution (₹7.69 Cr this quarter, ₹8.04 Cr a year ago) that boosted PBT is now a smaller share of a bigger revenue base — standalone PBT margin fell to 21.1% from 28.7% YoY. Readers comparing the two statements should treat consolidated as primary; the standalone number overstates margin softness because it strips out the subsidiaries that are growing faster and carrying the core operating margin.
The stock went into the print at ₹286.9, up 7.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Basic EPS ₹1.32 (consolidated) vs ₹0.99 in Q4 FY26 and ₹1.05 in Q1 FY26
Management guides for accelerated revenue growth in FY27, exceeding the 26.7% achieved in FY26, backed by a strong INR 1,000 crore order book. EBITDA margins, which faced pressure in Q4 from commodity prices and manpower investments, are expected to recover and improve in FY27 through operating leverage and a focus on
— This quarter: met
Against management's own prior guidance, the quarter is broadly on track: the board had guided to FY27 revenue growth exceeding FY26's 26.7%, and a pre-results earnings-call preview reiterated a target of 40-50% core-business growth and a ₹250-300 Cr quarterly run-rate. Q1's 43.1% YoY growth sits inside that growth band, though the ₹247.69 Cr print lands just under the low end of the run-rate target. No formal street PAT consensus could be located for this print, so vsStreet is unknown rather than assumed. Corporate activity was heavy this quarter and after it: the company incorporated Standard Projects Pvt Ltd (75% stake, immaterial P&L impact), and subsequent to quarter-end paid ₹125 Cr cash for a 33.55% stake in GScale Energy and remitted ₹71.47 Cr for a 19.19% stake in Japan's GL Hakko, alongside board-approved preferential allotments (~₹71.48 Cr, EGM scheduled August 10) to fund the wider capacity-doubling and new-sector (nuclear, oil & gas) strategy laid out on the last call. None of this capital deployment is in the Q1 P&L yet — it sets up Q2 as the first quarter where GScale and GL Hakko integration costs or contributions, and the margin-recovery trajectory, become testable against this quarter's guidance.
W1
Whether OPM continues its sequential recovery (13.91% in Q4 → 16.00% now) back toward the ~17% level seen a year ago, per management's stated FY27 margin-recovery guidance
W2
Whether quarterly revenue clears the ₹250-300 Cr run-rate management flagged, after Q1 printed just under that band at ₹247.69 Cr
W3
Consolidation and P&L contribution from GScale Energy (33.55% stake, ₹125 Cr paid) and GL Hakko (19.19%, ₹71.47 Cr) starting Q2, both closed after this quarter-end
Record Growth, Flat Margins—The Real Earnings Story
Revenue jumped 43% YoY to ₹248 Cr on pharma tailwinds, but operating margins stayed flat at 16% despite the scale. The call reveals why—and whether two new businesses can justify the capital bets ahead.
₹247.7 Cr
+43.1% YoY · +9.3% QoQ
16.0%
Flat YoY · vs 17.5% guided
₹26.7 Cr
+26.6% YoY
₹1,400 Cr
5.6x quarterly revenue
The margin gap: why 43% growth didn't flow to the bottom line
Standard Engineering delivered ₹248 Cr revenue—a record and a 43% YoY beat of prior guidance (26.7% baseline). But operating profit margins stayed locked at 16.0%, flat year-over-year. Management had guided for 17.5% EBITDA; the delivery was 150 basis points lower. That gap is the quarter's real story.
Why it happened: Two forces offset the operating leverage from 43% growth. First, the company invested heavily in mechanization capex across two manufacturing units—reducing consumable costs long-term, but adding depreciation and integration costs near-term. Second, manpower investments for GScale Energy (the new data center manufacturing unit) and headcount additions for CDMO technical support are flowing through as period costs, not capitalized. The call made clear these are temporary headwinds, but they hit Q1 hard and will persist through the capex cycle.
The main reason for decline is that we had done some mechanization in two units. As a result the consumption of the consumable items have been reduced.
The implication: profit growth (27% PAT YoY) has structurally lagged revenue growth (43% YoY) and will continue to do so until mechanization is amortized and GScale scales into its unit economics. Management maintained guidance for 17–18% EBITDA going forward, but the track record says margin recovery will be gradual, not sharp.
What changed on this call
Core business growth
40–50% FY27 growth; ₹1,200 Cr revenue
Raised. Q1 ₹248 Cr run-rate achieves this if sustained.
'Exceeding 26.7%' (FY26 baseline)
New business: GScale Energy
₹250 Cr revenue target by end FY27; ₹500 Cr capex over 2 years; data center integrated manufacturing
New bet. Unproven; factory ramp Nov 2026. Revenue recognition binary.
Not announced
GL Hakko partnership
₹71 Cr for 19.9% stake; 70-yr glass-lining tech license; path to 51% by FY28 if ₹400 Cr revenue hit
Strategic M&A. Tech moat real; IP concentration risk if partnership breaks.
Not announced
The headline: SETL is no longer a single-engine pharma glass-lining supplier. Management has engineered a two-engine thesis—core pharma/chemical growing 40–50% on a CDMO capex cycle peak, plus GScale data center manufacturing (optically diversifying into a 6x CAGR India market). GL Hakko brings exclusive glass-lining tech and a ₹2,000 Cr India TAM / USD 2B global TAM, but depends on a Japan partnership that limits India manufacturing to 20% (the other 80% is Japan-made for IP protection).
Management's claims vs. what holds up
'Record quarter, every quarter new numbers'—₹248 Cr revenue, 43.1% YoY growth
'EBITDA ₹44 Cr, 27% YoY growth'—math checks (₹44 Cr / ₹250 Cr revenue ≈ 17.6%); supported by backlog
'Operating margins 17.5% EBITDA'—delivered 16.0% OPM; 150 bps miss due to capex and manpower drag
'GScale ₹250 Cr revenue by end FY27'—factory ramp Nov 2026, LOIs only (no signed contracts), 4-month window to ₹250 Cr is 2.5x quarterly run-rate
'Core business ₹1,200 Cr FY27 (40–50% growth)'—Q1 ₹248 Cr annualized ≈ ₹1,048 Cr; requires acceleration mid-year or assumes Q2–Q4 surge
'Order book ₹1,400 Cr for core business'—stated on call, unverified externally; CDMO 50%, pharma/chemical 50% split
How the street is reading this
The market validated the print. SETL shares rose +3.75% on day 1 (result delivery 54.6% of volume), extended to +10.09% by day 3, and held +10.11% by day 5. The move suggests consensus viewed the 43% revenue growth and ₹1.4K Cr order book as concrete, with the margin miss seen as a temporary capex cycle effect, not structural decay. The stock is now ₹298.4, +2.8% below its all-time high of ₹307, comfortably above its 20-day SMA (₹282.54) and 200-day SMA (₹167.02). Volume is trending up. RSI 60.7 sits in neutral zone—no extreme overbought signal yet.
Ownership momentum: FII holdings increased 34 basis points QoQ to 2.77% (from 2.43%); DII trimmed slightly to 0.20% from 0.35%. Promoter stake remains rock-solid at 60.47%. The FII uptick into a growth story is consistent with the bullish tape, though the absolute FII weight (2.77%) remains modest—room for larger institutional entry if the GScale or GL Hakko stories de-risk.
Verdict: the post-result pop held, suggesting the market believes the quarter is a step-change (43% growth = new regime), not a temporary surge. But the stock sits near all-time highs with limited margin of safety. The ₹1.4K Cr order book is the floor of confidence; GScale factory commissioning in Nov 2026 is the make-or-break catalyst.
The bull-bear ledger
Core pharma/CDMO capex cycle is real and cyclically timed; ₹1,400 Cr order book is 5.6x quarterly revenue—durable floor
India glass-lining TAM is only ₹1,500 Cr; at ₹1,200 Cr FY27 run-rate, SETL will own ~80% of market—limit to organic growth >50% long-term
GScale data center thesis is strategically sound (India 6x CAGR market, hyper-scalers shifting manufacturing from China); but execution is binary and timeline aggressive
GL Hakko partnership unlocks ₹2,000 Cr India + USD 2B global TAM in glass-lining heat exchangers; 70-yr exclusive tech access is a 20-year moat
GL Hakko is 80% Japan-made for IP protection; no tech transfer currently committed. If partnership breaks, SETL loses moat and ₹71 Cr investment is at risk
Operating margins flat at 16% despite 43% growth—mechanization and GScale overhead are near-term drags, but recovery to 17–18% hinges on capex amortization and GScale unit economics proving out
Capital intensity is rising: ₹500 Cr capex over 2 years for GScale, on top of mechanization spend. If ROE doesn't materialize at 20% (as claimed), SETL dilutes core FCF
Management track record on prior guidance: FY26 26.7% growth beat. Forward 43.1% Q1 beat prior baseline. Credibility score B—high delivery, but hedged on forward commitments
Risks, ranked by what should concern a holder
GScale factory ramp and LOI-to-PO conversion. Five customer LOIs (3 global hyper-scalers, 2 India) exist; zero signed contracts disclosed. Nov 2026 commissioning + 4-month ₹250 Cr revenue window is binary.
HIGHIf GScale misses ₹250 Cr FY27, consolidated guidance (₹1,450 Cr) falls to ₹1,200 Cr core only. Raises questions on capital allocation efficiency and ROE claims (20% assumed). Valuation re-rates on single-engine narrative.
GL Hakko technology lock-in and IP risk. 80% of GL Hakko value is Japan-manufactured (IP protection). If partnership breaks, India operations (20%) can't scale and ₹71 Cr investment + future acquisition path (to 51% stake) is stranded.
HIGHGL Hakko is the crown jewel of FY27–FY28 story. If tech access is curtailed or partnership deteriorates, SETL loses the ₹2K Cr India TAM thesis and must revert to core pharma glass-lining (TAM-capped).
Core business TAM ceiling at ₹1,500 Cr India. Pharma glass-lining equipment market in India is saturated. At ₹1,200 Cr FY27, SETL owns ~80% of addressable market. Sustaining 40–50% growth beyond FY28 requires either international expansion or adjacent-product diversification.
MEDIUMGrowth guidance assumes CDMO capex cycle sustains through FY28; if pharma spending slows, core business reverts to low single-digit growth. Two-engine thesis masks a TAM-cap problem on the core.
Operating margin compression at scale. Q1 OPM 16% flat YoY despite 43% revenue growth. Manpower and capex investments cited as temporary, but if 40–50% growth continues, fixed-cost overhead will persist. Margin recovery guidance (17–18%) may be aspirational.
MEDIUMMargin miss vs. guidance erodes earnings quality. If OPM stays at 16% and revenue grows to ₹1,200 Cr FY27, implied EBITDA is ₹192 Cr (16% of ₹1,200 Cr), not ₹204+ Cr (17%+ of ₹1,200 Cr). ₹12 Cr earnings dilution at risk.
Capex execution and ROE realization. ₹500 Cr capex over 2 years is aggressive. Management claims 20% ROE on GScale; if capex overruns or revenue misses, ROE compresses to <15%, destroying capital allocation narrative.
MEDIUMGScale capex is 25% of current market cap (assumed). If execution slips or ROE lands at 12–15%, SETL destroys shareholder value vs. returning cash or organic growth invest in core.
What to watch next
1 · November 2026: GScale factory operationalization
Full commissioning of 2 lakh sqft manufacturing floor + robotic equipment. This is the gateway to any ₹250 Cr FY27 revenue. Delays push the thesis to FY28 and invalidate forward guidance.
2 · Q2 & Q3 FY27: Data center LOI-to-PO conversion rate
The 5 customer LOIs must convert to signed purchase orders with binding timelines. If conversion rate is <50% or order volumes are <₹50 Cr per customer, ₹250 Cr FY27 is unrealistic. This is when risk truly resolves.
3 · Q2 FY27 earnings: Operating margin path
Can OPM recover to 17%+ now that mechanization capex is cycling through P&L? If Q2 margins stay at 16% or compress below 15%, the 17–18% guidance is at risk and the two-engine thesis math breaks (can't both scale GScale and maintain margins).
The debate
The one number to track from here
Forget the headline revenue growth rate (43% is cyclical on CDMO capex). Watch operating profit margin. If OPM recovers to 17%+ by Q2 FY27, mechanization is amortizing and the business is de-leveraging—two-engine thesis is live. If OPM stays at 16% or dips to 15%, capex intensity is structural and margin recovery is pushed to FY28 or beyond. At ₹298 per share, you're betting on Q2 margin recovery + GScale factory success. Both need to happen for the stock to hold ₹300+. Conviction should be reassessed after GScale Nov 2026 commissioning and Q2 FY27 results (both expected 3 months out).
SETL is no longer a single-engine pharma supplier; it is executing a two-engine diversification story in real time. The core business is firing on cylinder—₹248 Cr Q1 revenue, ₹1.4K Cr order book, 43% growth—but capital is flowing to GScale and GL Hakko, depressing margins. The question is not whether the strategy makes sense long-term, but whether it will execute before the pharma capex cycle softens. The market has moved forward on confidence; execution over the next 12 months will determine whether the stock holds ₹300 or reverts to ₹210. Watch Nov 2026 and Q2 numbers closely.
Two-engine growth thesis, execution risk on unproven GScale pivot
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Prior guidance exceeded (26.7% → 43.1% achieved). Forward 40-50% growth raised vs prior; GScale ₹250 Cr by Dec is ambitious, unproven.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong core momentum (43% revenue growth, ₹1.4K Cr order book) and structural tailwinds (pharma CDMO capex, GL Hakko 70-yr tech, data center 6x CAGR). But Q1 operating margins flat at 16% despite 43% growth signals cost pressures; GScale is unproven with factory ramp November and ₹250 Cr revenue target crammed into 4-month window. Two-engine thesis is optically compelling but execution risk high on ₹500 Cr capex, data center commercialization, and margin recovery.
₹247.7 Cr
Revenue · +43.1% YoY₹26.7 Cr
Reported PAT · +26.6% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Record quarter, every quarter new numbers
MET₹247.7 Cr revenue, 43.1% YoY growth, in-line with historical growth
EBITDA ₹44 Cr, 27% YoY growth, margins 17.5%
METDelivered 16.0% OPM, 10.6% NPM; 44 Cr on 250 Cr = 17.6% margin. YoY EBITDA growth ~27% plausible
GScale ₹250 Cr revenue by end FY27
OVERSTATEDUnexecuted; factory ramp Nov 2026, only LOIs advanced. Revenue recognition risky 4-month window
Core business 40-50% growth, ₹1,200 Cr FY27
OVERSTATEDQ1 FY27 ₹247.7 Cr implies ~₹1,048 Cr annualized at current run-rate; 40-50% growth guidance requires acceleration
Order book ₹1,400 Cr for core business
UnverifiedStated on call, unverified externally; 50% CDMO, 50% pharma/chemical split claimed
Earnings quality
What changed since the last call
Core business growth guidance raised
UpgradePrior: 'exceeding 26.7%' (FY26 baseline). Current: 40-50% FY27. Driver: CDMO capex cycle, pharma customer tailwind.
New GScale data center business added
NewINR 250 Cr revenue guidance FY27. Factory 4 lakh sqft, ₹500 Cr capex, aims 23-25% EBITDA margin. Market: India data center 6x CAGR via AI/cloud.
GL Hakko stake increased to 19.9%
NewINR 71 Cr investment; 20-yr glass-lining heat exchanger license; 2-3 yr path to 51% stake. Target GL Hakko ₹200 Cr → ₹400 Cr revenue.
EBITDA margin outlook maintained
NeutralGuided 17-18% core EBITDA (prior: margin recovery expected). Q1 delivered 16.0% OPM; slight underperformance vs 17.5% EBITDA claim.
FY27 consolidated revenue target raised
UpgradePrior 3-yr aspiration: ₹1,600 Cr. Current: ₹1,450 Cr (₹1,200 core + ₹250 GScale) FY27. Interim pivot; clarity pending on FY28 consolidation.
The Q&A
Analysts pressed hard on GScale manufacturing vs assembly, capex ROI (20% claimed), customer risk (named Schneider/ABB partnerships withheld), and data center timeline credibility (24-36 mo standard → 18 mo claim). Management held firm on skid-mount differentiation, but deflected on specific product mix, margin profile, and customer concentration risk. Confidence moderate; several evasions on GL Hakko royalty terms, working capital tailwinds, and historical capex returns.
GScale business scope & margins — Raman KV
AnsweredPower products, cooling, modular systems. 5 active customer inquiries (3 global MNCs, 2 India). Target ₹250 Cr revenue FY27. Brahma: 23-25% EBITDA expected.
GL Hakko product differentiation — Viraj Mahadevia
AnsweredNo global competitors in shell & tube heat exchangers or low-leaching glass. Nageswara: 80% manufactured Japan (IP protection), 20% India assembly. TAM ₹2,000 Cr India, USD 2B global.
GScale capex & ROI — Rohit Ohri
PartialNageswara: 20% ROE expected, possibly higher. Will guide on exact revenue/ROA later.
GScale data center timeline — Arvind
AnsweredBrahma: Traditional 24-36 mo. GScale 15-18 mo via skid-mount pre-manufacturing. Reduces construction & integration time.
Core business order book split — Praveen
AnsweredNageswara: CDMO ~50%, balance pharma/chemical. Mix reflects capex cycle tailwind.
Working capital improvement drivers — Rahul Maheshwari
PartialNageswara: Inventory managed flat (same stock level), customer advances growing, receivables collection improving. GScale <150 days (project advances).
Margin recovery path — Sandhya
PartialOperating leverage + financial leverage mix. Maintain 17-18% going forward. Manpower investments + mechanization are temporary headwinds.
Export exposure & shipping cost impact — Raman KV
PartialNageswara: Q1 only 2-3% exports (global macro uncertainty). Q2 guidance 5-6%. Cost headwind acknowledged but no specific quantification.
GScale customer identity — Darshan
DodgedBrahma: 3 global hyper-scalers + 2 India data center players. Names withheld (NDAs). Excitement high, LOIs active.
Technology transfer risk GL Hakko — Arvind
AnsweredNageswara: No tech transfer agreement currently. Critical products stay Japan (IP protection vs competitors). Non-critical India-made.
Guidance
FY27 core ₹1,200 Cr (40-50% growth); GScale ₹250 Cr revenue
MediumCore: ₹1,200 Cr from ₹248 Q1 base requires 40-50% YoY. Backed by ₹1,400 Cr order book and CDMO capex cycle. GScale: factory ramp Nov, LOIs only, 4-month execution window high-risk.
FY27 consolidated ₹1,450 Cr (₹1,200 + ₹250 GScale + GL Hakko partial consolidation TBD)
LowGL Hakko ₹200 Cr baseline not yet consolidated; contribution unclear. GScale ₹250 Cr is 100% new business, unproven.
Core EBITDA 17-18% (maintain prior); GScale 23-25% (premium) at scale
MediumQ1 delivered 16.0% OPM vs claimed 17.5% EBITDA; slight miss. Manpower investments cited as temporary. GScale margin unproven; based on partner product benchmarks, not actual run.
₹500 Cr capex over 2 years for GScale; 4 lakh sqft facility (2 lakh sqft live by Nov 2026)
HighEquipment on order globally; mid-Sep arrival, Nov ops target. Phase 2 (2 lakh sqft) by Dec 2026. Phases 3 & 4 to follow.
Risks the call surfaced
GScale execution & revenue risk
High₹250 Cr FY27 target rests on Nov 2026 factory commissioning, 5 customer LOI conversions, and product-market fit in data center manufacturing. Zero revenue history. 4-month window for ₹250 Cr is 2.5x typical quarterly run-rate.
Customer concentration & data center moat
HighOnly 5 active data center customer inquiries. No long-term purchase commitments disclosed. Hyper-scalers (Amazon, Google, Meta) have bargaining power and can backward-integrate or switch suppliers. Moat based on 'integrated solution + speed' but replicable by incumbents (Schneider, ABB) if they choose to bundle.
GL Hakko technology lock-in & IP risk
Medium₹71 Cr investment at 19.9% stake; glass-lining critical products (80% of value) manufactured in Japan only, with no tech transfer commitment. If GL Hakko relationship breaks or technology is obsoleted, SETL loses moat. 2-3 yr path to 51% ownership depends on ₹400 Cr revenue milestone (DouBLING) — ambitious and unproven.
Core business margin compression
MediumQ1 OPM 16.0% vs guided 17.5% EBITDA; flat YoY despite 43% revenue growth. Manpower investments + mechanization capex offsetting scale. If revenue misses 40-50% growth, fixed cost leverage evaporates and margins compress further below 16%.
Core business TAM ceiling
MediumGlass-lining equipment TAM India ₹1,500 Cr only. Even at ₹1,200 Cr guided FY27, SETL will capture ~80% of total addressable market. Requires international expansion or adjacent products to sustain 40-50% growth beyond FY27-FY28.
Capex execution risk
Medium₹500 Cr capex over 2 years for GScale on aggressive timeline (2 lakh sqft by Nov 2026). Robotic equipment sourced globally mid-Sep arrival; civil + electrical integration concurrent. Delays could push revenue recognition to FY28, missing FY27 guidance.
Management
Score 7/10. Clear on business model and market strategy; confident tone on two-engine thesis. However, evasive on customer names (NDA shield) and specific GScale product mix / margin drivers. Deferred several forward-looking commitments to 'guide later,' reducing transparency. Strong track record on core business (43% YoY FY27 Q1 beat prior guidance 26.7% baseline). GScale unproven; factory ramp and LOI-to-PO conversion timeline aggressive but transparent about risks. GL Hakko partnership deal-making solid; tech access clear.
1 · Nov 2026
GScale factory operationalization; product line 1 & phase 2 commissioning expected
2 · Q2/Q3 FY27
Data center customer order book conversion; first LoIs expected to turn POs
3 · FY28
GL Hakko 32% stake acquisition trigger if ₹200 Cr → ₹400 Cr revenue milestone hit
Two-engine thesis is optically compelling but execution risk high on ₹500 Cr capex, data center commercialization, and margin recovery.